# AbbVie Acquires Apogee Therapeutics for $10.9 Billion to Deepen Immunology Pipeline

> ma · REPORTED · 2026-06-22

On June 22, 2026, AbbVie announced a definitive all-cash agreement to acquire Apogee Therapeutics at $135.11 per share, valued at approximately $10.9 billion, securing Apogee's lead asset zumilokibart, a late-stage half-life extended anti-IL-13 monoclonal antibody in Phase 3 for atopic dermatitis and asthma, along with a broader pipeline in inflammatory and immunological diseases.

- Company: AbbVie / Apogee Therapeutics
- Sector: biotech
- Primary source: https://news.abbvie.com/2026-06-22-AbbVie-to-Acquire-Apogee-Therapeutics,-Deepening-Immunology-Portfolio

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.